Cell and gene therapies have the potential to change the therapy landscape in many therapeutic areas with high unmet medical need. However, financing one-time treatments may also be a challenge for payers worldwide.
This session will focus on pay-for-performance & deferred payment models in Europe for cell and gene therapies. The panel will focus on presenting the various contract models, incentives and challenges for implementation, as well as criteria that drive the attractiveness of such models to industry and payers. Post launch evidence generation is often a critical element of those contracts to provide payers with long-term data. The panel will present and discuss examples of pay-for-performance models implemented with payers across Europe.
Session ID: 546639